| Document |
Document Title |
|
JP2021008504A |
To provide compounds and pharmaceutical compositions useful for prevention and treatment of CNS-related conditions.Compounds of a formula (I) in the figure are provided, where Z is selected from, e.g., a substituted or unsubstituted C1-C...
|
|
JP2020189880A |
To provide pyridine, pyridazine and triazine derivatives that are useful in the treatment of cancer.The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds a...
|
|
JP6777773B2 |
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v):and wherein L1, L2, L3, X1, X2, Y, RZ4, RZ5, RZ6, n, R1, R2, R3a, R3b, R4a,...
|
|
JP2020530031A |
The present invention relates to the field of prostate cancer treatment, particularly the field of prostate cancer treatment by androgen ablation therapy (ADT). This treatment involves oral administration of the estrol component in combi...
|
|
JP2020062050A |
To provide neuroactive steroids, compositions, and uses thereof.Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; and b) a...
|
|
JP2020063294A |
To synthesize new solid forms including salt forms of α-tocopheryloxyacetic acid (α-TEA) in view of the high degree of unmet medical need.There are provided salts of the compound represented by following formula, polymorphic forms ther...
|
|
JP6661643B2 |
The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile ...
|
|
JP2019535826A |
The present disclosure provides a method of treating or preventing cardiovascular disorders and / or associated lung disorders in a subject. In certain embodiments, the method comprises a therapeutically effective amount of an inhibitor ...
|
|
JP2019524864A |
The estrogen receptor β-selective ligand may be a compound that follows Structure 1: [Chemical Formula 1]. In the formula, m is 0, 1, or 2, and R is H, C.1~ C5Alkyl group, vinyl, CF3, CH2CH2F, CH2CHF2, Or CH2CF3Is. The composition (eg, ...
|
|
JP6568025B2 |
Compositions of deoxycholic acid (DCA) containing a steroidal DCA precursor or by-product containing a 12.beta.-hydroxy group (in particular 12.beta.-DCA) and their use in a cosmetic method of non-surgical removal of undesirable fat depo...
|
|
JP6542127B2 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...
|
|
JP2019068741A |
To provide algae that produce sterol, and a method for producing sterol using the same.Algae such as AJ7867 strain (FERM P-22304) and a strain derived therefrom, having a sterol production ability, are cultured. From bodies of the result...
|
|
JP6479912B2 |
The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of: a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of fo...
|
|
JP2019023206A |
To provide bifunctional compounds, which find utility as modulators of targeted ubiquitination and as inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited.Compounds contain on one end a ...
|
|
JP6437636B2 |
The present invention provides amphiphilic compounds with a tetradecahydrophenanthrene skeleton of formula (I), wherein R1-R5 are as defined herein, and their enantiomers, exhibiting neuroprotective effects, for use as medicaments for tr...
|
|
JP6433910B2 |
A levonorgestrel crystal mixture comprising polymorphic levonorgestrel crystals α which give an X-ray powder diffraction spectrum that has diffraction peaks at the following diffraction angles (α) in terms of 2θ and polymorphic levono...
|
|
JP6425540B2 |
The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of: a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of fo...
|
|
JP6393023B2 |
Compositions of deoxycholic acid (DCA) containing a steroidal DCA precursor or by-product containing a 12.beta.-hydroxy group (in particular 12.beta.-DCA) and their use in a cosmetic method of non-surgical removal of undesirable fat depo...
|
|
JP6356218B2 |
The present invention provides a class of fulvestrant ester derivatives and preparation method thereof. Such a compound is an aliphatic ester formed by esterifying the -OH at positions C-3 and C-17 of fulvestrant, having a structure of t...
|
|
JP6254289B2 |
The invention relates to a process for obtaining Estetrol or a salt or solvate thereof, the process comprising: a) reacting a compound of formula (IV) or a salt or solvate thereof, wherein R1 is a hydroxyl protecting group selected from ...
|
|
JP6238410B2 |
To provide chemical compounds useful as phosphorescent materials.A phosphorescent material comprises a chemical compound represented by the general formula (1). [Rto R, Rto R, Rto R, Rto Rare each independently H or a substituent; Ris an...
|
|
JP6228353B2 |
New methods are provided for synthesis of photoacid generator compounds ("PAGs"), new photoacid generator compounds and photoresist compositions that comprise such PAG compounds. In a particular aspect, sulfonium-containing (S+) photoaci...
|
|
JP2017160139A |
To provide a method for synthesizing a bi(hetero)aryl(thio)ether compound at low cost without discharging halogen-derived waste.The production method includes, for example as shown in the following formula, reacting a (thio)ester compoun...
|
|
JP6196625B2 |
The present invention relates to a process for the preparation of a compound of formula (I), hydrates or solvates thereof.
|
|
JP2017105827A |
To provide methods of halogenating a carbon-containing compound having an sp3 C-H bond.Methods of halogenating a carbon-containing compound having an sp3 C-H bond are provided. Methods of fluorinating a carbon-containing compound compris...
|
|
JP6125547B2 |
Provided are a new form of levonorgestrel, which is useful as an emergency contraception, etc., a solid dispersion of levonorgestrel, a manufacturing method for the same, and a drug composition. The differential scanning calorimetry sp...
|
|
JP6116550B2 |
The present invention relates to a process for the preparation of a compound of formula (I) comprising the steps of a) reacting a compound of formula (II) with a silylating or an acylating agent to produce compound of formula (III), wher...
|
|
JP6106328B2 |
The present invention discloses compound 2²,3±,5±-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
|
|
JP6100798B2 |
A process ethynylates 16-methylene-17-keto steroids to the corresponding 16-methylene-17α-ethynyl-17β-hydroxy steroids by treatment with silyl-protected lithium acetylides followed by further desilylation. The resulting products are us...
|
|
JP6097295B2 |
Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provi...
|
|
JP6091510B2 |
The present invention relates to a process for the preparation of 17-substituted steroids and, more particularly, to an improved method of synthesizing abiraterone or derivatives thereof in high yield and purity by means of a key 3-forma...
|
|
JP2017502031A |
The present invention relates to the synthesis of ent-progesterone and its intermediates. [Selection diagram] None
|
|
JP2016540507A |
Regarding a novel tripelten glycoside compound. In sweetener compounds, the monosaccharide units of monosaccharides and / or oligosaccharides are selected from the following groups: fructose, glucose, sucrose, xylose, maltose, mannose, r...
|
|
JP6025301B2 |
The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR 4 )-3-one structure for prophylactic and/or therapeutic uses, wherein R 4 is hydrogen or an unsubstituted or su...
|
|
JP5992397B2 |
A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
|
|
JP2016138113A |
To provide novel 6-substituted 13-demethyl-estradiol derivatives as selective ER-β agonists and analgesic agents comprising the same.There is provided a 6-substituted 13-demethyl-estradiol compound represented by the following formula, ...
|
|
JP2016521544A |
The present application relates to regioselective and stereoselective preparations of dehydroepiandrosterone (DHEA), as well as intermediates thereof. Dehydroepiandrosterone (DHEA) is an important intermediate in the synthesis of steroid...
|
|
JP5918170B2 |
Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treat...
|
|
JP5913253B2 |
The present invention relates to compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The compositions are useful for treating diseases sub...
|
|
JP5898625B2 |
Disclosed are compounds of the formula: wherein R1, R2, R3 and R4 are independently hydrogen, C1-C6 alkyl, halo, a sulfate, a glucuronide, —OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, —N(CH2)n; a phosphate grou...
|
|
JP2016041770A |
To provide methods and compositions for increasing telomerase activity in cells.Such compositions include pharmaceuticals, including topical and nutraceutical formulations. The methods and compositions are useful for treating diseases re...
|
|
JP5871500B2 |
|
|
JP2016505038A |
The present invention is a novel compound and composition of 11β-hydroxysteroids, as well as pharmaceuticals for preventing or reversing mitochondrial damage in human or animal subjects, for treating or preventing diseases associated wi...
|
|
JP2016027000A |
To provide a new steroidal compound useful as a medicine for diagnosis and a medicine comprising the same.The present invention provides a steroidal compound represented by formula (1) (where Ris a hydroxy group, a protecting hydroxy gro...
|
|
JP2016006090A |
To provide a novel crystal polymorphism of levonorgestrel which is useful as an emergency contraceptive or the like, and to provide a production method thereof, as well as to provide a pharmaceutical composition.The invention provides an...
|
|
JP2016006091A |
To provide a novel crystal polymorphism of levonorgestrel which is a steroid useful as an emergency contraceptive or the like, and to provide a production method thereof, as well as to provide a pharmaceutical composition containing the ...
|
|
JP5841337B2 |
The present invention relates to compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The compositions are useful for treating diseases sub...
|
|
JP2015212301A |
To provide a novel form of levonorgestrel which is useful as an emergency contraception, and the like, a solid dispersion of levonorgestrel, a manufacturing method for the same, and a drug composition.A solid dispersion of the invention ...
|
|
JP5809368B2 |
Provided are a new crystalline form of levonorgestrel, which is useful as an emergency contraception, etc., a manufacturing method for the same, and a drug composition. The powder X-ray diffraction spectrum of this β crystalline polym...
|
|
JP5809172B2 |
The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of disea...
|
